The Therapeutic Approaches for Hepatitis C Virus: Protease Inhibitors and Polymerase Inhibitors
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
The current standard of care for hepatitis C infection is peginterferon/ribavirin (PegIFN/RBV). We are entering the era where direct-acting antiviral agents (DAAs) will be added to PegIFN/RBV, leading to higher sustained response rates in genotype 1 infected individuals. Currently DAAs are directed toward specific proteins involved in hepatitis C replication with NS3/NS4A protease inhibitors furthest in development. Telaprevir and boceprevir are both NS3/NS4a inhibitors that significantly improve sustained response when added to PegIFN and RBV. The hepatitis C virus (HCV) polymerase inhibitors are another promising DAA class. These molecules are divided into nucleoside/nucleotide polymerase inhibitors and nonnucleotide/nucleoside polymerase inhibitors. Nucleoside/nucleotide polymerase inhibitors have a high barrier to resistance and appear to be effective across a broad range of genotypes. Nonnucleoside polymerase inhibitors have a lower barrier of resistance and appear to be genotype specifi c. Preliminary data with these compounds are also promising. A third class, NS5A inhibitors, has also shown potent HCV RNA suppression in preliminary studies as monotherapy and with PegIFN and RBV. Combinations of these agents are also entering clinical trials and indeed a preliminary report has demonstrated that the combination of an NS3/4A protease inhibitor and NS5B polymerase inhibitor can effectively suppress virus in genotype 1 individuals. Future studies will concentrate on combinations of direct-acting antiviral agents without and with PegIFN and RBV. Clinicians will need to be familiar with managing side effects as well as resistance as we enter this new era.
Abstract
The current standard of care for hepatitis C infection is peginterferon/ribavirin (PegIFN/RBV). We are entering the era where direct-acting antiviral agents (DAAs) will be added to PegIFN/RBV, leading to higher sustained response rates in genotype 1 infected individuals. Currently DAAs are directed toward specific proteins involved in hepatitis C replication with NS3/NS4A protease inhibitors furthest in development. Telaprevir and boceprevir are both NS3/NS4a inhibitors that significantly improve sustained response when added to PegIFN and RBV. The hepatitis C virus (HCV) polymerase inhibitors are another promising DAA class. These molecules are divided into nucleoside/nucleotide polymerase inhibitors and nonnucleotide/nucleoside polymerase inhibitors. Nucleoside/nucleotide polymerase inhibitors have a high barrier to resistance and appear to be effective across a broad range of genotypes. Nonnucleoside polymerase inhibitors have a lower barrier of resistance and appear to be genotype specifi c. Preliminary data with these compounds are also promising. A third class, NS5A inhibitors, has also shown potent HCV RNA suppression in preliminary studies as monotherapy and with PegIFN and RBV. Combinations of these agents are also entering clinical trials and indeed a preliminary report has demonstrated that the combination of an NS3/4A protease inhibitor and NS5B polymerase inhibitor can effectively suppress virus in genotype 1 individuals. Future studies will concentrate on combinations of direct-acting antiviral agents without and with PegIFN and RBV. Clinicians will need to be familiar with managing side effects as well as resistance as we enter this new era.
참고문헌 (46)
- Lauer GM, "Hepatitis C virus infection", N Engl J Med, 345, pp.41~52 (2001)
- Bartenschlager R, "Replication of hepatitis C virus", J Gen Virol, 81, pp.1631~1648 (2000)
- Hinrichsen H, "Short-term antiviral efficacy of BILN 2061, a hepatitis C virus serine protease inhibitor, in hepatitis C genotype 1 patients", Gastroenterology, 127, pp.1347~1355 (2004)
- Forestier N, "Antiviral activity of telaprevir (VX-950) and peginterferon alfa-2a in patients with hepatitis C", Hepatology, 46, pp.640~648 (2007)
- Zeuzem S, "Telaprevir, peginterferon alfa-2a, and ribavirin for 28 days in chronic hepatitis C patients", J Hepatol, 49, pp.157~159 (2008)
- McHutchison JG, "Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection", N Engl J Med, 360, pp.1827~1838 (2009)
- Hézode C, "Telaprevir and peginterferon with or without ribavirin for chronic HCV infection", N Engl J Med, 360, pp.1839~1850 (2009)
- McHutchison JG, "Telaprevir for previously treated chronic HCV infection", N Engl J Med, 362, pp.1292~1303 (2010)
- Malcolm BA, "SCH 503034, a mechanismbased inhibitor of hepatitis C virus NS3 protease, suppresses polyprotein maturation and enhances the antiviral activity of alpha interferon in replicon cells", Antimicrob Agents Chemother, 50, pp.1013~1020 (2006)
- Friedrich-Rust M, "Ultrasound evaluation of perihepatic lymph nodes during antiviral therapy with the protease inhibitor telaprevir (VX-950) in patients with chronic hepatitis C infection", Ultrasound Med Biol, 33, pp.1362~1367 (2007)
- Keeffe EB, "A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update", Clin Gastroenterol Hepatol, 6, pp.1315~1341 (2008)
- Kwo PY, "Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naïve patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial", Lancet, 376, pp.705~716 (2010)
- Poordad F, "Boceprevir for untreated chronic HCV genotype 1 infection", N Engl J Med, 364, pp.1195~1206 (2011)
- Bacon BR, "Boceprevir for previously treated chronic HCV genotype 1 infection", N Engl J Med, 364, pp.1207~1217 (2011)
- Forestier N, "Treatment of chronic hepatitis C patients with the NS3", 4A protease inhibitor danoprevir (ITMN-191, J Hepatol, pp.2011, 54[DOI]
- Gane EJ, "First-in-man demonstration of potent antiviral activity with a nucleoside polymerase (R7128) and protease (R7227", ITMN-191) inhibitor combination in HCV: safety, pharmacokinetics, and virologic results from INFORM-1, 2010, pp.50(Suppl 1), S380~
- Gane E, "Ritonavir boosting of low dose RG7227", ITMN-191, HCV NS3, J Hepatol, pp.2010, 52(Suppl 1)[DOI]
- Reesink HW, "Rapid HCV-RNA decline with once daily TMC435: a phase I study in healthy volunteers and hepatitis C patients", Gastroenterology, 138, pp.913~921 (2010)
- Marcellin P, "Antiviral activity and safety of TMC435 combined with peginterferon alpha-2a and ribavirin in patients with genotype 1 hepatitis C infection who failed previous IFN-based therapy", J Hepatol, 50(Suppl 1), pp.S385~ (2009)
- Sulkowski MS, "SILEN-C1: early antiviral activity and safety of BI 201335 combined with peginterferon alfa-2a and ribavirin in treatment-naïve patients with chronic genotype 1 HCV infection", Hepatology, 50(Suppl 4), pp.90A~ (2009)
- Sulkowski M, "SILEN-C2: early antiviral activity and safety of BI 201335 combined with peginterferon alfa-2a and ribavirin (PEGIFN", RBV) in chronic HCV genotype-1 patients with non-response to PEGIFN, J Hepatol, pp.2010, 52(Suppl 1)[DOI]
- Betzi S, "Identification of allosteric inhibitors blocking the hepatitis C virus polymerase NS5B in the RNA synthesis initiation step", Antiviral Res, 84, pp.48~59 (2009)
- Kim, Min Soo, "Selection and Target-Site Mapping of Peptides Inhibiting HCV NS5BPolymerase Using Phage Display", Journal of Microbiology and Biotechnology, 18(2), pp.328~333 (2008), 한국미생물·생명공학회
- Martin Hernando JI, "Optimization of thienopyrrole-based finger-loop inhibitors of the hepatitis C virus NS5B polymerase", ChemMedChem, 4, pp.1695~1713 (2009)
- McGowan D, "1,5-Benzodiazepine inhibitors of HCV NS5B polymerase", Bioorg Med Chem Lett, 19, pp.2492~2496 (2009)
- Reddy R, "Antiviral activity, pharmacokinetics, safety and tolerability of R7128, a novel nucleoside HCV RNA polymerase inhibitor, following multiple, ascending, oral doses in patients with HCV genotype 1 infection who have failed prior interferon therapy", Hepatology, 46(Suppl 1), pp.862A~ (2007)
- Lalezari J, "Potent antiviral activity of the HCV nucleoside polymerase inhibitor R7128 with PEG-IFN and ribavirin: interim results of R7128 500 mg bid for 28 days", J Hepatol, 48(Suppl 2), pp.S29~ (2008)
- Gane EJ, "Sustained virologic response (SVR) following RG7128 1500mg BID", PEG-IFN, 3 prior non-responders, pp.J Hepatol, 2010[DOI]
- Gane EJ, "Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial", Lancet, 376, pp.1467~1475 (2010)
- Lalezari J, "Antiviral activity, safety and pharmacokinetics of IDX184, a liver-targeted nucleotide HCV polymerase inhibitor, in patients with chronic hepatitis C", Hepatology, 50(Suppl 4), pp.228A~ (2009)
- Lalezari J, "Once daily PSI- 7977 plus PEGIFN", RBV in a phase 2B trial: rapid virologic suppression in treatment-naïve patients with HCV GT2, J Hepatol, pp.2011, 54(Suppl 1)[DOI]
- Larrey D, "Safety, pharmacokinetics and antiviral effect of BI 207127, a novel HCV RNA polymerase inhibitor, after 5 days oral treatment in patients with chronichepatitis C", J Hepatol, 50(Suppl 1), pp.S383~S384 (2009)
- Brainard DM, "Safety and antiviral activity of NS5B polymerase inhibitor MK-3281, in treatmentnaïve genotype 1A, 1B and 3 HCV-infected patients", Hepatology, 50(Suppl 4), pp.263A~ (2009)
- Erhardt A, "Safety, pharmacokinetics and antiviral effect of BILB1941, a novel HCV RNA polymerase inhibitor, after 5 days oral treatment in patients with chronic hepatitis C", J Hepatol, 46(Suppl 1), pp.S222~ (2007)
- Jacobson I, "Antiviral activity of filibuvir in combination with pegylated interferon alfa-2a and ribavirin for 28 days in treatment naïve patients chronically infected with HCV genotype 1", J Hepatol, 50(Suppl 1), pp.S382~S383 (2009)
- Rodriguez-Torres M, "Safety and antiviral activity of the HCV non-nucleoside polymerase inhibitor VX-222 in treatment-naïve genotype 1 HCV-infected patients", J Hepatol, 52(Suppl 1), pp.S14~ (2010)
- Lawitz E, "Safety and antiviral activity of ana598 in combination with pegylated interferon alpha2a plus ribavirin in treatment-naïve genotype-1 chronic HCV patients", J Hepatol, 52(Suppl 1), pp.S467~ (2010)
- Good SS, "Preclinical pharmacokinetic and safety profile of IDX375, a novel and potent nonnucleoside HCV polymerase inhibitor", J Hepatol, 50(Suppl 1), pp.S125~S126 (2009)
- Rodriguez-Torres M, "Treatment-naïve, HCV genotype 1-infected subjects show significantly greater HCV RNA decreases when treated with 28 days of ABT-333 plus peginterferon and ribavirin compared to peginterferon and ribavirin alone", Hepatology, 50(Suppl 4), pp.91A~ (2009)
- Bavisotto L, "Antiviral, pharmacokinetic and safety data for GS-9190, a non-nucleoside HCV NS5B polymerase inhibitor in a phase-1 trial in HCV genotype 1 infected subjects", Hepatology, 46(Suppl 1), pp.255A~ (2007)
- Shih I, "Mechanistic characterization of GS-9190, a novel non-nucleoside inhibitor of HCV NS5B polymerase with potent antiviral activity and a unique mechanism of action", Hepatology, 46(Suppl 1), pp.859A~ (2007)
- Gao M, "Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect", Nature, 465, pp.96~100 (2010)
- Nettles R, "BMS-790052 is a first-in-class potent hepatitis C virus (HCV) NS5A inhibitor for patients with chronic HCV infection: results from a proof-of-concept study", Hepatology, 48(Suppl 1), pp.1025A~ (2008)
- Pol S, "Once-daily NS5A inhibitor (BMS-790052) plus peginterferon-alpha-2a and ribavirin produces high rates of extended rapid virologic response in treatment-naïve HCV-genotype 1 subjects: phase 2a trial", J Hepatol, 52(Suppl 1), pp.S462~ (2010)
- Gane E, "Antiviral activity, pharmacokinetics, and tolerability of AZD7295, a novel NS5A inhibitor, in a placebo-controlled multiple ascending dose study in HCV genotype 1 and 3 patients", J Hepatol, 52(Suppl 1), pp.S464~ (2010)
- Colonno R, "Identification and characterization of PPI-461, a potent and selective HCV NS5A inhibitor with activity against all HCV genotypes", J Hepatol, 52(Suppl 1), pp.S14~S15 (2010)